CONMED (CNMD) Target, Estimates Lifted at Needham & Company

February 13, 2014 3:47 PM

Needham & Company analyst Mike Matson reiterated a Buy rating and raised his price target on CONMED (NASDAQ: CNMD) from ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found